Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Change in Receivables of -$19.0 million for Q1 2026, down 90.0% year-over-year from -$190.0 million in Q1 2025, and down 156.16% quarter-over-quarter from $33.8 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Change in Receivables for 9 consecutive years, with -$19.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 90.0% year-over-year to -$19.0 million; the TTM figure through Mar 2026 stood at $22.0 million (up 2522.91% YoY), while the FY2025 annual figure was $31.0 million, down 8.82% from the prior year.
- Change in Receivables retreated to -$19.0 million in Q1 2026 per RARE's latest filing, from $33.8 million in the prior quarter.
- Across five years, Change in Receivables topped out at $33.8 million in Q4 2025 and bottomed at -$19.0 million in Q1 2026.
- Historically, Change in Receivables has averaged $4.8 million across 5 years, with a median of $2.5 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Receivables sank 955.56% — and 2023, when it soared 7700.0%.
- Ultragenyx Pharmaceutical's Change in Receivables stood at $9.1 million in 2022, then slumped by 108.69% to -$790000.0 in 2023, then soared by 2763.54% to $21.0 million in 2024, then surged by 60.79% to $33.8 million in 2025, then sank by 156.16% to -$19.0 million in 2026.
- Business Quant data shows RARE's Change in Receivables at -$19.0 million in Q1 2026, $33.8 million in Q4 2025, and -$5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 62.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.00 Mn |
| Jun 30, 2026 | 62.00 Mn |
| Mar 31, 2026 | -19.00 Mn |
| Mar 31, 2026 | -19.00 Mn |
| Dec 31, 2025 | 33.83 Mn |
| Dec 31, 2025 | 33.83 Mn |
| Sep 30, 2025 | -5.43 Mn |
| Sep 30, 2025 | -5.43 Mn |
| Jun 30, 2025 | 12.59 Mn |
| Jun 30, 2025 | 12.59 Mn |
| Mar 31, 2025 | -10.00 Mn |
| Mar 31, 2025 | -10.00 Mn |
| Dec 31, 2024 | 21.04 Mn |
| Dec 31, 2024 | 21.04 Mn |
| Sep 30, 2024 | -9.79 Mn |
| Sep 30, 2024 | -9.79 Mn |
| Jun 30, 2024 | -2.16 Mn |
| Jun 30, 2024 | -2.16 Mn |
| Mar 31, 2024 | 24.91 Mn |
| Mar 31, 2024 | 24.91 Mn |